<DOC>
	<DOCNO>NCT01144026</DOCNO>
	<brief_summary>This protocol represent second human study TUTI-16 , conduct continue gather safety human immunogenicity ( anti-HIV-1 Tat titer ) data subcutaneously administer TUTI-16 .</brief_summary>
	<brief_title>Clinical Study TUTI-16 HIV-1 Infected Uninfected Subjects</brief_title>
	<detailed_description>HIV-1 Tat protein , virally encode toxin , secrete HIV-1 infected cell act uninfected cell , render permissive HIV-1 replication . HIV-1 Tat enhance chronic viral replication induces immune suppression . Antibodies Tat inhibit Tat-mediated transcellular activation vitro minimize chronic plasma viremia . HIV-1 Tat activity block vitro vivo anti-Tat antibody . The Thymon Universal Tat Immunogen ( TUTI-16 ) fully synthetic , self-adjuvanting lipopeptide vaccine water soluble administer subcutaneous injection . In preclinical study , prim dose three week boost rat induce high titer antibody response eight know distinct epitope variant HIV-1 Tat protein . These antibody block function HIV-1 Tat protein ( toxin ) , essential maintenance chronic HIV-1 viremia . Therefore , TUTI-16 potential therapeutic vaccine HIV-1 human .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Males Females Age ≥18 ≤50 year Screening HIV negative healthy subject HIV1 seropositive subject effective ART &gt; 2 month ( undetectable HIV plasma viremia ) , viral set point ART &gt; 3,000 CD4+ Tcell count ≥ 500/mm3 . Pregnant/nursing female Positive HBV HCV Acute Herpetic event Any clinically significant outof range laboratory value Routine PRN consumption immune suppressive medication subject unable unwilling discontinue study Participation another investigational drug/vaccine study within 30 day precede first injection investigational agent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>vaccine</keyword>
	<keyword>lipopeptide</keyword>
	<keyword>Tat</keyword>
	<keyword>TUTI-16</keyword>
	<keyword>THYMON</keyword>
</DOC>